NCT00708110 - Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572

GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.

DRUG

Placebo

Placebo is a tablet with no drug in it.

Trial Locations (18)

20009

GSK Investigational Site, Washington D.C.

28209

GSK Investigational Site, Charlotte

30308

GSK Investigational Site, Atlanta

32803

GSK Investigational Site, Orlando

32960

GSK Investigational Site, Vero Beach

33306

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

75204

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

80220

GSK Investigational Site, Denver

87505

GSK Investigational Site, Santa Fe

90813

GSK Investigational Site, Long Beach

91325

GSK Investigational Site, Northridge

92663

GSK Investigational Site, Newport Beach

93301

GSK Investigational Site, Bakersfield

94115

GSK Investigational Site, San Francisco

08844

GSK Investigational Site, Hillsborough

08043

GSK Investigational Site, Voorhees Township